{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:01:49Z","timestamp":1791576109764,"version":"4.3.4"},"reference-count":251,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Spanish Ministry of Economy and Competitiveness","award":["SAF 2015-66275-C2-R"],"award-info":[{"award-number":["SAF 2015-66275-C2-R"]}]},{"DOI":"10.13039\/501100006049","name":"Consejo Superior de Investigaciones Cient\u00edficas, Spain","doi-asserted-by":"publisher","award":["201580E073"],"award-info":[{"award-number":["201580E073"]}],"id":[{"id":"10.13039\/501100006049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006049","name":"Consejo Superior de Investigaciones Cient\u00edficas, Spain","doi-asserted-by":"publisher","award":["201880E109"],"award-info":[{"award-number":["201880E109"]}],"id":[{"id":"10.13039\/501100006049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Biochemistry and Biophysics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.abb.2018.10.011","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T15:24:43Z","timestamp":1539789883000},"page":"36-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Recent progress in non-opioid analgesic peptides"],"prefix":"10.1016","volume":"660","author":[{"given":"M. Jes\u00fas","family":"P\u00e9rez de Vega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2973-6607","authenticated-orcid":false,"given":"Antonio","family":"Ferrer-Montiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-4328","authenticated-orcid":false,"given":"Rosario","family":"Gonz\u00e1lez-Mu\u00f1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abb.2018.10.011_bib1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1126\/science.aaf8933","article-title":"Neural circuits for pain: recent advances and current views","volume":"354","author":"Peirs","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.abb.2018.10.011_bib2","article-title":"Pain therapeutics: current and future treatment paradigms","volume":"35","author":"Allerton","year":"2014","journal-title":"RSC Drug Discov Ser"},{"key":"10.1016\/j.abb.2018.10.011_bib3","first-page":"649","article-title":"Cumulative NCE introduction index, 1983\u20132017 (by indication)","volume":"50","year":"2017","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib4","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.ddtec.2011.07.007","article-title":"Opioid peptides: potential for drug development","volume":"9","author":"Aldrich","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.abb.2018.10.011_bib5","first-page":"543","article-title":"From natural peptides to market","volume":"50","author":"Schteingart","year":"2017","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib6","series-title":"Handbook of Ion Channels","first-page":"595","article-title":"Ion channels in pain","author":"Johnson","year":"2015"},{"key":"10.1016\/j.abb.2018.10.011_bib7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.biocel.2006.11.016","article-title":"Pain signalling pathways: from cytokines to ion channels","volume":"39","author":"Okuse","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.abb.2018.10.011_bib8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3390\/toxins9110372","article-title":"G-protein coupled receptors targeted by analgesic venom peptides","volume":"9","author":"Daniel","year":"2017","journal-title":"Toxins"},{"key":"10.1016\/j.abb.2018.10.011_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.wneu.2018.01.116","article-title":"Potential uses of isolated toxin peptides in neuropathic pain relief: a literature review","volume":"113","author":"Hamad","year":"2018","journal-title":"World Neurosurg"},{"key":"10.1016\/j.abb.2018.10.011_bib10","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.4155\/fmc.14.99","article-title":"Cone snail venomics: from novel biology to novel therapeutics","volume":"6","author":"Prashanth","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1039\/9781849737876-00221","article-title":"Therapeutic applications of spider- venom peptides","volume":"42","author":"Smith","year":"2015","journal-title":"RSC Drug Discov Ser"},{"key":"10.1016\/j.abb.2018.10.011_bib12","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/1568026043451663","article-title":"New trends in the development of opioid peptide analogues as advanced remedies for pain relief","volume":"4","author":"Gentilucci","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib14","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.2174\/092986706778742954","article-title":"Novel approaches to pain relief using venom-derived peptides","volume":"13","author":"Hogg","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1517\/13543784.2014.856879","article-title":"Investigational peptide and peptidomimetic \u03bc and \u03b4 opioid receptor agonists in the relief of pain","volume":"23","author":"Giri","year":"2014","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.abb.2018.10.011_bib16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1124\/mol.112.083337","article-title":"Dynorphin-still an extraordinarily potent opioid peptide","volume":"83","author":"Chavkin","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jcpt.12244","article-title":"Delta opioid agonists: a concise update on potential therapeutic applications","volume":"40","author":"Peppin","year":"2015","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.abb.2018.10.011_bib18","first-page":"357","article-title":"Endorphins: endogenous opioid in human cells, World","volume":"4","author":"Sharma","year":"2015","journal-title":"J. Pharm. Pharmaceut. Sci."},{"key":"10.1016\/j.abb.2018.10.011_bib19","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2174\/0929867323666160427123005","article-title":"Cyclic opioid peptides","volume":"23","author":"Remesic","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.peptides.2018.01.011","article-title":"Endogenous opiates and behavior: 2016","volume":"101","author":"Bodnar","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.10.011_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.brainresrev.2008.12.021","article-title":"Role of voltage-gated calcium channels in ascending pain pathways","volume":"60","author":"Zamponi","year":"2009","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.abb.2018.10.011_bib22","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/bph.13789","article-title":"Calcium channel modulation as a target in chronic pain control","volume":"175","author":"Patel","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2015.5","article-title":"Targeting voltage-gated calcium channels in neurological and psychiatric diseases","volume":"15","author":"Zamponi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.abb.2018.10.011_bib24","doi-asserted-by":"crossref","unstructured":"Q. Kaas, D.J. Craik, Conotoxins and other conopeptides, in: S. La Barre, J.-M. Komprobst (Eds.), Oustanding Marine Molecules, Wiley-Blackwell2014, pp. 319-332.","DOI":"10.1002\/9783527681501.ch14"},{"key":"10.1016\/j.abb.2018.10.011_bib25","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4155\/fmc.12.70","article-title":"Therapeutic potential of conopeptides","volume":"4","author":"Schroeder","year":"2012","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib26","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/ner.12392","article-title":"Intrathecal ziconotide: dosing and administration strategies in patients with refractory chronic pain","volume":"19","author":"McDowell","year":"2016","journal-title":"Neuromodulation"},{"key":"10.1016\/j.abb.2018.10.011_bib27","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(10)60354-6","article-title":"Ziconotide for treatment of severe chronic pain","volume":"375","author":"Schmidtko","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.abb.2018.10.011_bib28","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1038\/srep12497","article-title":"Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers","volume":"5","author":"Anand","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.abb.2018.10.011_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/mol.109.058834","article-title":"Analgesic \u03c9-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels","volume":"77","author":"Berecki","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1744-8069-6-97","article-title":"Analgesic effect of highly reversible \u03c9-conotoxin FVIA on N type Ca2+ channels","volume":"6","author":"Lee","year":"2010","journal-title":"Mol. Pain"},{"key":"10.1016\/j.abb.2018.10.011_bib31","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/s41598-017-18479-4","article-title":"A novel \u03b1-conopeptide Eu1.6 inhibits N-type (CaV2.2) calcium channels and exhibits potent analgesic activity","volume":"8","author":"Liu","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.abb.2018.10.011_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4161\/chan.4.1.10281","article-title":"Analgesic \u03b1-conotoxins Vc1.1 and RgIA inhibit N-type calcium channels in sensory neurons of \u03b19 nicotinic receptor knockout mice","volume":"4","author":"Callaghan","year":"2010","journal-title":"Channels"},{"key":"10.1016\/j.abb.2018.10.011_bib33","doi-asserted-by":"crossref","first-page":"10233","DOI":"10.1074\/jbc.M110.196170","article-title":"Structure and activity of \u03b1-conotoxin PeIA at nicotinic acetylcholine receptor subtypes and GABAB receptor-coupled N-type calcium channels","volume":"286","author":"Daly","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10571-012-9871-x","article-title":"An evaluation of the antinociceptive effects of Ph\u03b11\u03b2, a neurotoxin from the spider phoneutria nigriventer, and \u03c9-conotoxin MVIIA, a cone snail Conus magus toxin, in rat model of inflammatory and neuropathic pain","volume":"33","author":"Souza","year":"2013","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.abb.2018.10.011_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.toxicon.2014.01.015","article-title":"The effects of Ph\u03b11\u03b2, a spider toxin, calcium channel blocker, in a mouse fibromyalgia model","volume":"81","author":"Hubner de Souza","year":"2014","journal-title":"Toxicon"},{"key":"10.1016\/j.abb.2018.10.011_bib36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.lfs.2017.06.018","article-title":"Synergistic antinociceptive effect of a calcium channel blocker and a TRPV1 blocker in an acute pain model in mice","volume":"182","author":"Palhares","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.abb.2018.10.011_bib37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1472-8206.2009.00686.x","article-title":"Analgesic properties of S100A9 C-terminal domain: a mechanism dependent on calcium channel inhibition","volume":"23","author":"Dale","year":"2009","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib38","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.peptides.2008.05.023","article-title":"Antinociceptive effect of the C-terminus of murine S100A9 protein on experimental neuropathic pain","volume":"29","author":"Paccola","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.10.011_bib39","first-page":"297","article-title":"Does nature do ion channel drug discovery better than us?","volume":"39","author":"Lewis","year":"2015","journal-title":"RSC Drug Discov Ser"},{"key":"10.1016\/j.abb.2018.10.011_bib40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cbpa.2017.03.004","article-title":"Progress and challenges in the optimization of toxin peptides for development as pain therapeutics","volume":"38","author":"Netirojjanakul","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.abb.2018.10.011_bib41","doi-asserted-by":"crossref","first-page":"263\/1","DOI":"10.3389\/fphar.2015.00263","article-title":"Post-translational modifications of voltage-gated sodium channels in chronic pain syndromes","volume":"6","author":"Laedermann","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.abb.2018.10.011_bib42","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/j.pain.0000000000000368","article-title":"Potassium channels in neuropathic pain: advances, challenges, and emerging ideas","volume":"157","author":"Busserolles","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.abb.2018.10.011_bib43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1021\/acschemneuro.7b00406","article-title":"Selective voltage-gated sodium channel peptide toxins from animal venom: pharmacological probes and analgesic drug development","volume":"9","author":"Wu","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.abb.2018.10.011_bib44","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1111\/bph.13865","article-title":"Modulatory features of the novel spider toxin \u03bc-TRTX-Df1a isolated from the venom of the spider Davus fasciatus","volume":"174","author":"Cardoso","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib45","doi-asserted-by":"crossref","first-page":"7093","DOI":"10.1021\/jm501981g","article-title":"Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications","volume":"58","author":"de Lera Ruiz","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib46","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.tips.2017.11.010","article-title":"Nav1.7 as a pharmacogenomic target for pain: moving toward precision medicine","volume":"39","author":"Yang","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.abb.2018.10.011_bib47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1399-0004.2007.00790.x","article-title":"Loss\u2010of\u2010function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations","volume":"71","author":"Goldberg","year":"2007","journal-title":"Clin. Genet."},{"key":"10.1016\/j.abb.2018.10.011_bib48","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature05413","article-title":"An SCN9A channelopathy causes congenital inability to experience pain","volume":"444","author":"Cox","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.abb.2018.10.011_bib49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jmg.2003.012153","article-title":"Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia","volume":"41","author":"Yang","year":"2004","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.abb.2018.10.011_bib50","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.neuron.2006.10.006","article-title":"SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes","volume":"52","author":"Fertleman","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.abb.2018.10.011_bib51","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.toxicon.2012.04.337","article-title":"Spider-venom peptides that target voltage-gated sodium channels: pharmacological tools and potential therapeutic leads","volume":"60","author":"Klint","year":"2012","journal-title":"Toxicon"},{"key":"10.1016\/j.abb.2018.10.011_bib52","doi-asserted-by":"crossref","first-page":"40883","DOI":"10.1038\/srep40883","article-title":"Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a","volume":"7","author":"Deuis","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.abb.2018.10.011_bib53","doi-asserted-by":"crossref","first-page":"17534","DOI":"10.1073\/pnas.1306285110","article-title":"Discovery of a selective Nav1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models","volume":"110","author":"Yang","year":"2013","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.abb.2018.10.011_bib55","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1021\/jm501765v","article-title":"Engineering potent and selective analogs of gptx-1, a tarantula venom peptide antagonist of the NaV1.7 sodium channel","volume":"58","author":"Murray","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib56","doi-asserted-by":"crossref","first-page":"47564","DOI":"10.1074\/jbc.M204063200","article-title":"Function and solution structure of Huwentoxin-IV, a potent neuronal tetrodotoxin (TTX)-sensitive sodium channel antagonist from Chinese bird spider selenocosmia huwena","volume":"277","author":"Peng","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib57","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.peptides.2013.03.011","article-title":"Potency optimization of Huwentoxin-IV on hNav1.7: a neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider Selenocosmia huwena","volume":"44","author":"Revell","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.10.011_bib58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/09298665113206660119","article-title":"Analgesic effects of Huwentoxin-IV on animal models of inflammatory and neuropathic pain","volume":"21","author":"Liu","year":"2014","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.abb.2018.10.011_bib59","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.3390\/toxins6082363","article-title":"Synthesis and analgesic effects of \u03bc-TRTX-Hhn1b on models of inflammatory and neuropathic pain","volume":"6","author":"Liu","year":"2014","journal-title":"Toxins"},{"key":"10.1016\/j.abb.2018.10.011_bib60","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1124\/mol.115.098178","article-title":"Identification and characterization of ProTx-III [\u03bc-TRTX-Tp1a], a new voltage-gated sodium channel inhibitor from venom of the tarantula Thrixopelma pruriens","volume":"88","author":"Cardoso","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib61","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1124\/mol.108.047670","article-title":"ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors","volume":"74","author":"Schmalhofer","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib62","doi-asserted-by":"crossref","first-page":"14734","DOI":"10.1021\/bi026546a","article-title":"Two tarantula peptides inhibit activation of multiple sodium channels","volume":"41","author":"Middleton","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.abb.2018.10.011_bib63","doi-asserted-by":"crossref","first-page":"E2018","DOI":"10.1073\/pnas.1120800109","article-title":"Transient opening of the perineurial barrier for analgesic drug delivery","volume":"109","author":"Hackel","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.abb.2018.10.011_bib64","doi-asserted-by":"crossref","first-page":"39662","DOI":"10.1038\/srep39662","article-title":"Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor","volume":"7","author":"Flinspach","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.abb.2018.10.011_bib65","doi-asserted-by":"crossref","first-page":"7404","DOI":"10.1021\/bi060159+","article-title":"Synthetic \u03bcO-conotoxin MrVIB blocks TTX-resistant sodium channel NaV1.8 and has a long-lasting analgesic activity","volume":"45","author":"Bulaj","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.abb.2018.10.011_bib66","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.toxicon.2013.06.012","article-title":"Expression and secretion of functional recombinant \u03bcO-conotoxin MrVIB-His-tag in Escherichia coli","volume":"72","author":"Gao","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.abb.2018.10.011_bib67","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.bcp.2012.05.008","article-title":"Isolation, characterization and total regioselective synthesis of the novel \u03bcO-conotoxin MfVIA from Conus magnificus that targets voltage-gated sodium channels","volume":"84","author":"Vetter","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib68","doi-asserted-by":"crossref","first-page":"11829","DOI":"10.1074\/jbc.M116.721662","article-title":"Development of a \u03bco-conotoxin analogue with improved lipid membrane interactions and potency for the analgesic sodium channel NaV1.8","volume":"291","author":"Deuis","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib69","doi-asserted-by":"crossref","first-page":"22079","DOI":"10.1074\/jbc.M109.013276","article-title":"The first gene-encoded amphibian neurotoxin","volume":"284","author":"You","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib70","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.biochi.2011.02.010","article-title":"Analgesic and anti-inflammatory effects of the amphibian neurotoxin, anntoxin","volume":"93","author":"Wei","year":"2011","journal-title":"Biochimie"},{"key":"10.1016\/j.abb.2018.10.011_bib71","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fphar.2018.00186","article-title":"Novel sodium channel inhibitor from leeches","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib72","doi-asserted-by":"crossref","first-page":"13373","DOI":"10.1073\/pnas.231376298","article-title":"Distinct potassium channels on pain-sensing neurons","volume":"98","author":"Rasband","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.abb.2018.10.011_bib73","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/psc.2988","article-title":"Centipede venom peptide SsmTX-I with two intramolecular disulfide bonds shows analgesic activities in animal models","volume":"23","author":"Wang","year":"2017","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.abb.2018.10.011_bib74","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/psc.2588","article-title":"Isolation and characterization of SsmTx\u2010I, a specific Kv2.1 blocker from the venom of the centipede Scolopendra subspinipes mutilans L. Koch","volume":"20","author":"Chen","year":"2014","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.abb.2018.10.011_bib75","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/SPC.0000000000000131","article-title":"Emerging potassium channel targets for the treatment of pain","volume":"9","author":"Tsantoulas","year":"2015","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.abb.2018.10.011_bib76","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1124\/jpet.105.085928","article-title":"Tertiapin-Q blocks recombinant and native large conductance K+ channels in a use-dependent manner","volume":"314","author":"Kanjhan","year":"2005","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.abb.2018.10.011_bib77","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.toxicon.2013.10.027","article-title":"Vietnamese Heterometrus laoticus scorpion venom: evidence for analgesic and anti-inflammatory activity and isolation of new polypeptide toxin acting on Kv1.3 potassium channel","volume":"77","author":"Hoang","year":"2014","journal-title":"Toxicon"},{"key":"10.1016\/j.abb.2018.10.011_bib78","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bcp.2012.01.021","article-title":"Purification, molecular cloning and functional characterization of HelaTx1 (Heterometrus laoticus): the first member of a new \u03ba-KTX subfamily","volume":"83","author":"Vandendriessche","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib79","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1134\/S1607672913020142","article-title":"Hetlaxin, a new toxin from the Heterometrus laoticus scorpion venom, interacts with voltage-gated potassium channel Kv1.3","volume":"449","author":"Anh","year":"2013","journal-title":"Dokl. Biochem. Biophys."},{"key":"10.1016\/j.abb.2018.10.011_bib80","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.bcp.2013.08.001","article-title":"Neuronal nicotinic receptors as analgesic targets: it's a winding road","volume":"86","author":"Umana","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib81","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.toxicon.2006.07.023","article-title":"Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor","volume":"48","author":"Livett","year":"2006","journal-title":"Toxicon"},{"key":"10.1016\/j.abb.2018.10.011_bib82","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/aps.2009.47","article-title":"Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors","volume":"30","author":"Azam","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.abb.2018.10.011_bib83","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.3390\/md12052970","article-title":"Conotoxins targeting nicotinic acetylcholine receptors: an overview","volume":"22","author":"Lebbe","year":"2014","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.abb.2018.10.011_bib84","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.brainres.2005.08.009","article-title":"Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones","volume":"1059","author":"Satkunanathan","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.abb.2018.10.011_bib85","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/mol.114.096156","article-title":"Novel mechanism of voltage-gated n-type (cav2.2) calcium channel inhibition revealed through \u03b1-conotoxin Vc1.1 activation of the GABABB receptor","volume":"87","author":"Huynh","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib86","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/gutjnl-2015-310971","article-title":"\u03b1-Conotoxin Vc1.1 inhibits human dorsal root ganglion neuroexcitability and mouse colonic nociception via GABAB receptors","volume":"66","author":"Castro","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.abb.2018.10.011_bib87","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1124\/mol.107.040568","article-title":"Are \u03b19\u03b110 nicotinic acetylcholine receptors a pain target for \u03b1-conotoxins?","volume":"72","author":"Nevin","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib88","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.3390\/toxins7103916","article-title":"Conotoxin interactions with \u03b19\u03b110-nAChRs: is the \u03b19\u03b110-nicotinic acetylcholine receptor an important therapeutic target for pain management?","volume":"7","author":"Mohammadi","year":"2015","journal-title":"Toxins"},{"issue":"5","key":"10.1016\/j.abb.2018.10.011_bib89","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/bi0520129","article-title":"\u03b1-RgIA:\u2009 A novel conotoxin that specifically and potently blocks the \u03b19\u03b110 nAChR","volume":"45","author":"Ellison","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.abb.2018.10.011_bib90","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.pain.2014.06.023","article-title":"\u03b1-Conotoxin RgIA protects against the development of nerve injury-induced chronic pain and prevents both neuronal and glial derangement","volume":"155","author":"Di Cesare Mannelli","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.abb.2018.10.011_bib91","doi-asserted-by":"crossref","first-page":"E1825","DOI":"10.1073\/pnas.1621433114","article-title":"Inhibition of \u03b19\u03b110 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain","volume":"114","author":"Romero","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.abb.2018.10.011_bib92","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/j.peptides.2006.04.016","article-title":"Discovery of a novel class of conotoxin from Conus litteratus, lt14a, with a unique cysteine pattern","volume":"27","author":"Peng","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.10.011_bib93","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.toxicon.2015.01.013","article-title":"Pharmacological characterization of conotoxin lt14a as a potent non-addictive analgesic","volume":"96","author":"Ren","year":"2015","journal-title":"Toxicon"},{"key":"10.1016\/j.abb.2018.10.011_bib94","doi-asserted-by":"crossref","first-page":"E4026","DOI":"10.1073\/pnas.1503617112","article-title":"Cloning, synthesis, and characterization of \u03b1O-conotoxin GeXIVA, a potent \u03b19\u03b110 nicotinic acetylcholine receptor antagonist","volume":"112","author":"Luo","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.abb.2018.10.011_bib95","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0014-5793(00)01982-7","article-title":"Arginine-rich peptides are blockers of VR-1 channels with analgesic activity","volume":"481","author":"Planells Cases","year":"2000","journal-title":"FEBS Lett."},{"key":"10.1016\/j.abb.2018.10.011_bib96","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.1021\/jm070612v","article-title":"Design and synthesis of indole-based peptoids as potent noncompetitive antagonists of transient receptor potential vanilloid 1","volume":"50","author":"Quintanar-Audelo","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib97","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.3390\/toxins7093671","article-title":"Scorpion toxin, BmP01, induces pain by targeting TRPV1 channel","volume":"7","author":"Hakim","year":"2015","journal-title":"Toxins"},{"key":"10.1016\/j.abb.2018.10.011_bib98","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.cell.2010.03.052","article-title":"A bivalent tarantula toxin activates the capsaicin receptor, TRPV1, by targeting the outer pore domain","volume":"141","author":"Bohlen","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.abb.2018.10.011_bib99","doi-asserted-by":"crossref","first-page":"23914","DOI":"10.1074\/jbc.M800776200","article-title":"Analgesic compound from sea anemone Heteractis crispa is the first polypeptide inhibitor of vanilloid receptor 1 (TRPV1)","volume":"283","author":"Andreev","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib100","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.3390\/md11125100","article-title":"Polypeptide modulators of TRPV1 produce analgesia without hyperthermia","volume":"11","author":"Andreev","year":"2013","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.abb.2018.10.011_bib101","doi-asserted-by":"crossref","first-page":"E229","DOI":"10.3390\/md14120229","article-title":"Kunitz-type peptide HCRG21 from the sea anemone Heteractis crispa is a full antagonist of the TRPV1 receptor","volume":"14","author":"Monastyrnaya","year":"2016","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.abb.2018.10.011_bib102","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.peptides.2016.01.003","article-title":"ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: integration between immune system and nociception","volume":"76","author":"Zhang","year":"2016","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.10.011_bib103","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1744-8069-10-13","article-title":"ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response","volume":"10","author":"Swartjes","year":"2014","journal-title":"Mol. Pain"},{"key":"10.1016\/j.abb.2018.10.011_bib104","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.neuroscience.2012.12.022","article-title":"The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model","volume":"233","author":"Pulman","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.abb.2018.10.011_bib105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/bph.13652","article-title":"The peptide Ph\u03b11\u03b2, from spider venom, acts as a TRPA1 channel antagonist with antinociceptive effects in mice","volume":"174","author":"Tonello","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib106","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cub.2014.01.013","article-title":"A tarantula-venom peptide antagonizes the TRPA1 nociceptor ion channel by binding to the S1-S4 gating domain","volume":"24","author":"Gui","year":"2014","journal-title":"Curr. Biol."},{"key":"10.1016\/j.abb.2018.10.011_bib107","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1021\/co500005x","article-title":"De novo designed library of linear helical peptides: an exploratory tool in the discovery of protein-protein interaction modulators","volume":"16","author":"Bonache","year":"2014","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.abb.2018.10.011_bib108","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/toxins9050154","article-title":"New disulfide-stabilized fold provides sea anemone peptide to exhibit both antimicrobial and TRPA1 potentiating properties","volume":"9","author":"Logashina","year":"2017","journal-title":"Toxins"},{"key":"10.1016\/j.abb.2018.10.011_bib109","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1074\/jbc.M116.757369","article-title":"Peptide from sea anemone Metridium senile affects transient receptor potential ankyrin-repeat 1 (TRPA1) function and produces analgesic effect","volume":"292","author":"Logashina","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib110","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1097\/j.pain.0000000000000669","article-title":"Crotalphine desensitizes TRPA1 ion channels to alleviate inflammatory hyperalgesia","volume":"157","author":"Bressan","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.abb.2018.10.011_bib111","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainres.2017.12.013","article-title":"CB1 cannabinoid receptor agonist mouse VD-hemopressin(\u03b1) produced supraspinal analgesic activity in the preclinical models of pain","volume":"1680","author":"Zheng","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.abb.2018.10.011_bib112","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neulet.2014.04.042","article-title":"Somatostatin 4 receptor activation modulates TRPV1[correction of TPRV1] currents in dorsal root ganglion neurons","volume":"573","author":"Gorham","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.abb.2018.10.011_bib113","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrn3529","article-title":"Acid-sensing ion channels in pain and disease","volume":"14","author":"Wemmie","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.abb.2018.10.011_bib114","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuropharm.2015.01.005","article-title":"Pharmacology of acid-sensing ion channels - physiological and therapeutical perspectives","volume":"94","author":"Baron","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.abb.2018.10.011_bib115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.toxicon.2006.09.026","article-title":"Peptides inhibitors of acid-sensing ion channels","volume":"49","author":"Diochot","year":"2007","journal-title":"Toxicon"},{"key":"10.1016\/j.abb.2018.10.011_bib116","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/sj.emboj.7600177","article-title":"A new sea anemone peptide, APETx2, inhibits ASIC3, a major acid-sensitive channel in sensory neurons","volume":"23","author":"Diochot","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.abb.2018.10.011_bib117","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1111\/bph.14089","article-title":"Inhibition of acid-sensing ion channels by diminazene and APETx2 evoke partial and highly variable antihyperalgesia in a rat model of inflammatory pain","volume":"175","author":"Lee","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib118","doi-asserted-by":"crossref","first-page":"9195","DOI":"10.1021\/jm501400p","article-title":"Understanding the molecular basis of toxin promiscuity: the analgesic sea anemone peptide APETx2 interacts with acid-sensing ion channel 3 and hERG channels via overlapping pharmacophores","volume":"57","author":"Jensen","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib119","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.peptides.2018.04.013","article-title":"New APETx-like peptides from sea anemone Heteractis crispa modulate ASIC1a channels","volume":"104","author":"Kalina","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.10.011_bib120","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/nn1940","article-title":"A tarantula peptide against pain via ASIC1a channels and opioid mechanisms","volume":"10","author":"Mazzuca","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.abb.2018.10.011_bib121","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1111\/bph.13267","article-title":"Molecular dynamics and functional studies define a hot spot of crystal contacts essential for PcTx1 inhibition of acid-sensing ion channel 1a","volume":"172","author":"Saez","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib122","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature11494","article-title":"Black mamba venom peptides target acid-sensing ion channels to abolish pain","volume":"490","author":"Diochot","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.abb.2018.10.011_bib123","doi-asserted-by":"crossref","first-page":"43617","DOI":"10.1038\/srep43617","article-title":"Acid-Sensing Ion Channel 1a in the amygdala is involved in pain and anxiety-related behaviours associated with arthritis","volume":"7","author":"Aissouni","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.abb.2018.10.011_bib124","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nature10607","article-title":"A heteromeric Texas coral snake toxin targets acid-sensing ion channels to produce pain","volume":"479","author":"Bohlen","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.abb.2018.10.011_bib125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1254\/jjp.87.261","article-title":"Spinorphin, an endogenous inhibitor of enkephalin-degrading enzymes, potentiates Leu-enkephalin-induced anti-allodynic and antinociceptive effects in mice","volume":"87","author":"Honda","year":"2001","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib126","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1021\/jm070114m","article-title":"Structure-activity relationship studies of spinorphin as a potent and selective human P2X3 receptor antagonist","volume":"50","author":"Jung","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib127","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/ana.21949","article-title":"Novel peptide from spider venom inhibits P2X3 receptors and inflammatory pain","volume":"67","author":"Grishin","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.abb.2018.10.011_bib128","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nm.2710","article-title":"Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity","volume":"18","author":"Sorge","year":"2012","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.abb.2018.10.011_bib129","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1054\/npep.2000.0843","article-title":"The \u03b32-MSH peptide mediates a central analgesic effect via a GABA-ergic mechanism that is independent from activation of melanocortin receptors","volume":"35","author":"Klusa","year":"2001","journal-title":"Neuropeptides"},{"key":"10.1016\/j.abb.2018.10.011_bib130","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.npep.2008.09.003","article-title":"NR2B-selective conantokin peptide inhibitors of the NMDA receptor display enhanced antinociceptive properties compared to non-selective conantokins","volume":"42","author":"Xiao","year":"2008","journal-title":"Neuropeptides"},{"key":"10.1016\/j.abb.2018.10.011_bib131","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/physrev.00031.2013","article-title":"Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease","volume":"94","author":"Steinhoff","year":"2014","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.abb.2018.10.011_bib132","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1111\/bph.13907","article-title":"The Arg-Phe-amide peptide 26RFa\/glutamine RF-amide peptide and its receptor: IUPHAR Review 24","volume":"174","author":"Leprince","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib133","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.biopha.2017.03.053","article-title":"A review of the role of orexin system in pain modulation","volume":"90","author":"Razavi","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.abb.2018.10.011_bib134","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","article-title":"The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine","volume":"158","author":"Iyengar","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.abb.2018.10.011_bib135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fnins.2014.00023","article-title":"Calcitonin gene-related peptide is a key neurotransmitter in the neuro-immune axis","volume":"8","author":"Assas","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.abb.2018.10.011_bib136","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/bph.12129","article-title":"CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?","volume":"170","author":"Walker","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib137","doi-asserted-by":"crossref","first-page":"18345","DOI":"10.1073\/pnas.1420252111","article-title":"\u03b1CGRP is essential for algesic exocytotic mobilization of TRPV1 channels in peptidergic nociceptors","volume":"111","author":"Devesa","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"Suppl 2","key":"10.1016\/j.abb.2018.10.011_bib138","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/head.13081","article-title":"The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine","volume":"57","author":"Edvinsson","year":"2017","journal-title":"Headache"},{"key":"10.1016\/j.abb.2018.10.011_bib139","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1474-4422(13)70067-X","article-title":"Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study","volume":"12","author":"Amin","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.abb.2018.10.011_bib140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coph.2008.12.007","article-title":"CGRP receptors in the control of pain and inflammation","volume":"9","author":"Benemei","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib141","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.nurt.2010.02.004","article-title":"CGRP receptor antagonism and migraine","volume":"7","author":"Edvinsson","year":"2010","journal-title":"Neurother"},{"key":"10.1016\/j.abb.2018.10.011_bib142","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s13311-018-0617-4","article-title":"Targeted CGRP small molecule antagonists for acute migraine therapy","volume":"15","author":"Holland","year":"2018","journal-title":"Neurother"},{"key":"10.1016\/j.abb.2018.10.011_bib143","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.abb.2018.10.011_bib144","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.abb.2018.10.011_bib145","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/bph.13366","article-title":"Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches","volume":"173","author":"Lackovic","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib146","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/bph.12072","article-title":"Structure-activity relationships for \u03b1-calcitonin gene-related peptide","volume":"170","author":"Watkins","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib147","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib148","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41586-018-0535-y","article-title":"Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor","volume":"561","author":"Liang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.abb.2018.10.011_bib149","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ejp.1146","article-title":"Role of central versus peripheral opioid system in antinociceptive and anti-inflammatory effect of botulinum toxin type A in trigeminal region","volume":"22","author":"Drinovac Vlah","year":"2018","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.abb.2018.10.011_bib150","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1096\/fj.09-134346","article-title":"Differential contribution of SNARE-dependent exocytosis to inflammatory potentiation of TRPV1 in nociceptors","volume":"23","author":"Camprubi-Robles","year":"2009","journal-title":"Faseb. J."},{"key":"10.1016\/j.abb.2018.10.011_bib151","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fphar.2016.00178","article-title":"Bradykinin induces TRPV1 exocytotic recruitment in peptidergic nociceptors","volume":"7","author":"Mathivanan","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib152","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1124\/jpet.111.190678","article-title":"An inhibitor of neuronal exocytosis (DD04107) displays long-lasting in vivo activity against chronic inflammatory and neuropathic pain","volume":"341","author":"Ponsati","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.abb.2018.10.011_bib153","doi-asserted-by":"crossref","first-page":"9675","DOI":"10.1074\/jbc.M113.455162","article-title":"Potentiation of the transient receptor potential vanilloid 1 channel contributes to pruritogenesis in a rat model of liver disease","volume":"288","author":"Belghiti","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib154","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrd3673","article-title":"Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain","volume":"11","author":"Roques","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.abb.2018.10.011_bib155","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1054\/plef.2001.0362","article-title":"Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy","volume":"66","author":"Rice","year":"2002","journal-title":"Prostag Leukotr Ess"},{"key":"10.1016\/j.abb.2018.10.011_bib156","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0165-6147(99)01339-5","article-title":"Pharmacological and biochemical interactions between opioids and cannabinoids","volume":"20","author":"Manzanares","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.abb.2018.10.011_bib157","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/clpt.2011.188","article-title":"Cannabinoid\u2013opioid interaction in chronic pain","volume":"90","author":"Abrams","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.abb.2018.10.011_bib158","doi-asserted-by":"crossref","first-page":"20588","DOI":"10.1073\/pnas.0706980105","article-title":"Hemopressin is an inverse agonist of CB1 cannabinoid receptors","volume":"104","author":"Heimann","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.abb.2018.10.011_bib159","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.peptides.2004.10.026","article-title":"Antinociceptive action of hemopressin in experimental hyperalgesia","volume":"26","author":"Dale","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.10.011_bib160","doi-asserted-by":"crossref","first-page":"10449","DOI":"10.1021\/bi1011833","article-title":"Binding of the hemopressin peptide to the cannabinoid CB1 receptor: structural insights","volume":"49","author":"Scrima","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.abb.2018.10.011_bib161","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.pbb.2011.09.004","article-title":"Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception","volume":"100","author":"Hama","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.abb.2018.10.011_bib162","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1213\/ANE.0b013e31824c4eeb","article-title":"The effects of peptide and lipid endocannabinoids on arthritic pain at the spinal level","volume":"114","author":"Petrovszki","year":"2012","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.abb.2018.10.011_bib163","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2174\/0929866523666161007152435","article-title":"Hemopressin peptides as modulators of the endocannabinoid system and their potential applications as therapeutic tools","volume":"23","author":"Macedonio","year":"2016","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.abb.2018.10.011_bib164","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1096\/fj.09-132142","article-title":"Novel endogenous peptide agonists of cannabinoid receptors","volume":"23","author":"Gomes","year":"2009","journal-title":"Faseb. J."},{"key":"10.1016\/j.abb.2018.10.011_bib165","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/jpet.113.209866","article-title":"Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(\u03b1)], an N-terminally extended hemopressin peptide","volume":"348","author":"Han","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.abb.2018.10.011_bib166","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.npep.2016.12.006","article-title":"Pharmacological characterization of rat VD-hemopressin(\u03b1), an \u03b1-hemoglobin-derived peptide exhibiting cannabinoid agonist-like effects in mice","volume":"63","author":"Zheng","year":"2017","journal-title":"Neuropeptides"},{"key":"10.1016\/j.abb.2018.10.011_bib167","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/nmo.12789","article-title":"Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice","volume":"28","author":"Li","year":"2016","journal-title":"Neuro Gastroenterol. Motil."},{"key":"10.1016\/j.abb.2018.10.011_bib168","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.brainresbull.2018.02.003","article-title":"Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(\u03b2) in mice","volume":"139","author":"Wang","year":"2018","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.abb.2018.10.011_bib169","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/01.HYP.29.1.483","article-title":"Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors","volume":"29","author":"Alfie","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.abb.2018.10.011_bib170","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1021\/jm1000776","article-title":"Bradykinin B1 receptor antagonists as potential therapeutic agents for pain","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib171","first-page":"113","article-title":"Bradykinin B2 receptor antagonists for the treatment of pain","volume":"39","author":"Dziadulewicz","year":"2004","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib172","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1476-5381.1991.tb12249.x","article-title":"Hoe 140 a new potent and long acting bradykinin\u2010antagonist: in vivo studies","volume":"102","author":"Wirth","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib173","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0304-3959(93)90080-9","article-title":"Antinociceptive activity of the bradykinin B1 and B2 receptor antagonists, des-Arg9, [Leu8]-BK and HOE 140, in two models of persistent hyperalgesia in the rat","volume":"53","author":"Perkins","year":"1993","journal-title":"Pain"},{"key":"10.1016\/j.abb.2018.10.011_bib174","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S1734-1140(13)71082-X","article-title":"Dose-depending effect of intracerebroventricularly administered bradykinin on nociception in rats","volume":"65","author":"Bujalska-Zadro\u017cny","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.abb.2018.10.011_bib175","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/sj.bjp.0707275","article-title":"Inhibition of acute nociceptive responses in rats after i.c.v. injection of Thr6-bradykinin, isolated from the venom of the social wasp, Polybia occidentalis","volume":"151","author":"Mortari","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib176","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1021\/jm800704e","article-title":"Engineering stabilized vascular endothelial growth factor-A antagonists: synthesis, structural characterization, and bioactivity of grafted analogues of cyclotides","volume":"51","author":"Gunasekera","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib177","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1002\/anie.201200984","article-title":"Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment","volume":"51","author":"Wong","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.abb.2018.10.011_bib178","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0014-2999(86)90687-4","article-title":"The actions of kinin antagonists on B1 and B2 receptor systems","volume":"123","author":"Regoli","year":"1986","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib179","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/acs.jmedchem.6b01011","article-title":"An orally active bradykinin B1 receptor antagonist engineered as a bifunctional chimera of sunflower trypsin inhibitor","volume":"60","author":"Qiu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib180","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.peptides.2006.04.025","article-title":"Neurotensin and pain modulation","volume":"27","author":"Dobner","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.abb.2018.10.011_bib181","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2013.03.004","article-title":"Neurotensin and neurotensin receptors: characteristic, structure-activity relationship and pain modulation-A review","volume":"716","author":"Kleczkowska","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib182","doi-asserted-by":"crossref","first-page":"8188","DOI":"10.1523\/JNEUROSCI.0810-05.2005","article-title":"Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors","volume":"25","author":"Sarret","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.abb.2018.10.011_bib183","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1744-8069-5-38","article-title":"Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity","volume":"5","author":"Roussy","year":"2009","journal-title":"Mol. Pain"},{"key":"10.1016\/j.abb.2018.10.011_bib184","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.brainres.2009.07.086","article-title":"NT69L, a novel analgesic, shows synergy with morphine","volume":"1294","author":"Boules","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.abb.2018.10.011_bib185","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/jm200006c","article-title":"Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics","volume":"54","author":"Einsiedel","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib186","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cmdc.201200376","article-title":"Development of a metabolically stable neurotensin receptor 2 (NTS2) ligand","volume":"8","author":"Held","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.abb.2018.10.011_bib187","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1016\/j.bmc.2015.01.053","article-title":"Improved radiosynthesis and preliminary in vivo evaluation of a 18F-labeled glycopeptide-peptoid hybrid for PET imaging of neurotensin receptor 2","volume":"23","author":"Maschauer","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib188","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1021\/jm100092s","article-title":"Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic","volume":"53","author":"Hughes","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib189","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1021\/jm700925k","article-title":"Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood-brain barrier","volume":"51","author":"Bredeloux","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib190","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1021\/acs.jmedchem.5b00841","article-title":"Synthesis and characterization in vitro and in vivo of (L)-(Trimethylsilyl)alanine containing neurotensin analogues","volume":"58","author":"Fanelli","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib191","doi-asserted-by":"crossref","first-page":"13752","DOI":"10.1074\/jbc.274.20.13752","article-title":"Contulakin-G, an O-glycosylated invertebrate neurotensin","volume":"274","author":"Craig","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib192","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/cpdd.253","article-title":"Phase IA clinical trial evaluating the tolerability, pharmacokinetics, and analgesic efficacy of an intrathecally administered neurotensin a analogue in central neuropathic pain following spinal cord injury","volume":"5","author":"Sang","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.abb.2018.10.011_bib193","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fphar.2015.00011","article-title":"A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties","volume":"6","author":"Lee","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib194","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1172\/JCI70647","article-title":"Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties","volume":"124","author":"Demeule","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.abb.2018.10.011_bib195","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1744-8069-6-86","article-title":"PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects","volume":"6","author":"Kleczkowska","year":"2010","journal-title":"Mol. Pain"},{"key":"10.1016\/j.abb.2018.10.011_bib196","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.brainres.2016.07.039","article-title":"Antinociceptive effect induced by a combination of opioid and neurotensin moieties vs. their hybrid peptide [Ile9]PK20 in an acute pain treatment in rodents","volume":"1648","author":"Kleczkowska","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.abb.2018.10.011_bib197","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1734-1140(13)71064-8","article-title":"Identification of Dmt-D-Lys-Phe-Phe-OH as a highly antinociceptive tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20","volume":"65","author":"Kleczkowska","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.abb.2018.10.011_bib198","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0024-3205(03)00546-0","article-title":"Antinociception induced by \u03b2-lactotensin, a neurotensin agonist peptide derived from \u03b2-lactoglobulin, is mediated by NT2 and D1 receptors","volume":"73","author":"Yamauchi","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.abb.2018.10.011_bib199","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd1852","article-title":"Chemokines: integrators of pain and inflammation","volume":"4","author":"White","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.abb.2018.10.011_bib200","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pain.2011.09.022","article-title":"Attenuation of rodent neuropathic pain by an orally active peptide, RAP-103, which potently blocks CCR2- and CCR5-mediated monocyte chemotaxis and inflammation","volume":"153","author":"Padi","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.abb.2018.10.011_bib201","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.1002\/anie.201000620","article-title":"The engineering of an orally active conotoxin for the treatment of neuropathic pain","volume":"49","author":"Clark","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.abb.2018.10.011_bib202","doi-asserted-by":"crossref","first-page":"6984","DOI":"10.1021\/jm201060r","article-title":"Effects of cyclization on stability, structure, and activity of \u03b1-conotoxin RgIA at the \u03b19\u03b110 nicotinic acetylcholine receptor and GABA(B) receptor","volume":"54","author":"Halai","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib203","doi-asserted-by":"crossref","first-page":"13385","DOI":"10.1074\/jbc.M113.522680","article-title":"Development of a membrane-anchored chemerin receptor agonist as a novel modulator of allergic airway inflammation and neuropathic pain","volume":"289","author":"Doyle","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/156802607779318316","article-title":"Emerging therapeutic opportunities by targeting protein-protein interactions","volume":"7","author":"Gonzalez-Muniz","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib205","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/anie.200200558","article-title":"Modulation of protein-protein interactions with small organic molecules","volume":"42","author":"Berg","year":"2003","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.abb.2018.10.011_bib206","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/anie.201107616","article-title":"Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?","volume":"51","author":"Thiel","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.abb.2018.10.011_bib207","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.phrs.2015.10.015","article-title":"Receptome: interactions between three pain-related receptors or the \"Triumvirate\" of cannabinoid, opioid and TRPV1 receptors","volume":"102","author":"Zador","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.abb.2018.10.011_bib208","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neulet.2013.06.057","article-title":"Challenging the catechism of therapeutics for chronic neuropathic pain: targeting CaV2.2 interactions with CRMP2 peptides","volume":"557","author":"Feldman","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.abb.2018.10.011_bib209","doi-asserted-by":"crossref","first-page":"31375","DOI":"10.1074\/jbc.M109.009951","article-title":"An atypical role for collapsin response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels","volume":"284","author":"Brittain","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib210","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.2345","article-title":"Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca2+ channel complex","volume":"17","author":"Brittain","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.abb.2018.10.011_bib211","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4161\/chan.5.5.17363","article-title":"Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex","volume":"5","author":"Wilson","year":"2011","journal-title":"Channels"},{"key":"10.1016\/j.abb.2018.10.011_bib212","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/jnc.12070","article-title":"Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide","volume":"124","author":"Ju","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.abb.2018.10.011_bib213","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1111\/bph.13737","article-title":"Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides","volume":"175","author":"Moutal","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib214","doi-asserted-by":"crossref","first-page":"35065","DOI":"10.1074\/jbc.M112.378695","article-title":"Inhibition of transmitter release and attenuation of anti-retroviral-associated and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides","volume":"287","author":"Wilson","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib215","doi-asserted-by":"crossref","first-page":"24316","DOI":"10.1074\/jbc.M113.474924","article-title":"CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking","volume":"288","author":"Dustrude","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib216","series-title":"Non-narcotic CRMP2-derived Peptides Targeting Sodium Channels for Pain, WO2105134920","author":"Khanna","year":"2015"},{"key":"10.1016\/j.abb.2018.10.011_bib217","doi-asserted-by":"crossref","first-page":"7407","DOI":"10.1523\/JNEUROSCI.3721-12.2013","article-title":"Disrupting sensitization of transient receptor potential vanilloid subtype 1 inhibits inflammatory hyperalgesia","volume":"33","author":"Fischer","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.abb.2018.10.011_bib218","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1523\/JNEUROSCI.4991-12.2013","article-title":"Mapping the binding site of TRPV1 on AKAP79: implications for inflammatory hyperalgesia","volume":"33","author":"Btesh","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.abb.2018.10.011_bib219","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.neuron.2014.12.065","article-title":"Tmem100 is a regulator of TRPA1-TRPV1 complex and contributes to persistent pain","volume":"85","author":"Weng","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.abb.2018.10.011_bib220","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1096\/fj.08-107425","article-title":"Identification of molecular determinants of channel gating in the transient receptor potential box of vanilloid receptor I","volume":"22","author":"Valente","year":"2008","journal-title":"Faseb. J."},{"key":"10.1016\/j.abb.2018.10.011_bib221","doi-asserted-by":"crossref","first-page":"28579","DOI":"10.1074\/jbc.M114.577478","article-title":"The region adjacent to the C-end of the inner gate in transient receptor potential melastatin 8 (TRPM8) channels plays a central role in allosteric channel activation","volume":"289","author":"Taberner","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib222","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1085\/jgp.201311070","article-title":"Mutation of 1696 and W697 in the TRP box of vanilloid receptor subtype I modulates allosteric channel activation","volume":"143","author":"Gregorio-Teruel","year":"2014","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.abb.2018.10.011_bib223","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bpj.2015.06.039","article-title":"The integrity of the TRP domain is pivotal for correct TRPV1 channel gating","volume":"109","author":"Gregorio-Teruel","year":"2015","journal-title":"Biophys. J."},{"key":"10.1016\/j.abb.2018.10.011_bib224","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1096\/fj.10-174433","article-title":"Membrane-tethered peptides patterned after the TRP domain (TRPducins) selectively inhibit TRPV1 channel activity","volume":"25","author":"Valente","year":"2011","journal-title":"Faseb. J."},{"key":"10.1016\/j.abb.2018.10.011_bib225","series-title":"Peptide Modulators of Specific Calcineurin Protein-protein Interactions, WO 2017156128","author":"Gross","year":"2017"},{"key":"10.1016\/j.abb.2018.10.011_bib226","series-title":"Peptides blocking the interaction between NMDA-binding glutamate receptors and Src kinase for use in analgesia, US20070059320","author":"Salter","year":"2007"},{"key":"10.1016\/j.abb.2018.10.011_bib227","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11916-011-0183-5","article-title":"Growth factors and neuropathic pain","volume":"15","author":"Ossipov","year":"2011","journal-title":"Curr. Pain Headache Rep."},{"key":"10.1016\/j.abb.2018.10.011_bib228","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/BOR.0000000000000354","article-title":"Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?","volume":"29","author":"Miller","year":"2017","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.abb.2018.10.011_bib229","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.39492","article-title":"When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program","volume":"68","author":"Hochberg","year":"2016","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.abb.2018.10.011_bib230","series-title":"Preparation of Amino Acid and Peptide Prodrugs of Phenolic Analgesics with Increased Oral BioavailabilityWO2009092071A2","author":"Franklin","year":"2009"},{"key":"10.1016\/j.abb.2018.10.011_bib231","series-title":"Preparation of Amino Acid and Peptide Carbamate Prodrugs of Tapentadol for Providing Pain Relief with an Increased Oral Bioavailability and Reduced Gastrointestinal Side Effects, WO2010100477A2","author":"Golding","year":"2010"},{"key":"10.1016\/j.abb.2018.10.011_bib232","series-title":"Novel Carbamate Amino Acid and Peptide Prodrugs of Opiates and Uses Thereof, US20120270847A1","author":"Franklin","year":"2012"},{"key":"10.1016\/j.abb.2018.10.011_bib233","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/cmdc.201100504","article-title":"Dipeptidyl peptidase IV (DPPIV\/CD26)-based prodrugs of hydroxy-containing drugs","volume":"7","author":"Diez-Torrubia","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.abb.2018.10.011_bib234","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejmech.2017.10.083","article-title":"Amino acid and peptide prodrugs of diphenylpropanones positive allosteric modulators of \u03b17 nicotinic receptors with analgesic activity","volume":"143","author":"Balsera","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib235","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jpain.2014.09.004","article-title":"A pain research agenda for the 21st century","volume":"15","author":"Gereau","year":"2014","journal-title":"J. Pain"},{"key":"10.1016\/j.abb.2018.10.011_bib236","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.neuroscience.2018.02.002","article-title":"Extracellular application of CRMP2 increases cytoplasmic calcium through NMDA receptors","volume":"376","author":"Castillo","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.abb.2018.10.011_bib237","doi-asserted-by":"crossref","first-page":"7470","DOI":"10.1074\/jbc.M113.518472","article-title":"Collapsin response mediator protein 2 (CRMP2) interacts with N-Methyl-D-aspartate (NMDA) receptor and Na+\/Ca2+ exchanger and regulates their functional activity","volume":"289","author":"Brustovetsky","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib238","doi-asserted-by":"crossref","first-page":"427","DOI":"10.15252\/embj.201796692","article-title":"Mapping protein interactions of sodium channel NaV1.7 using epitope-tagged gene-targeted mice","volume":"37","author":"Kanellopoulos","year":"2018","journal-title":"EMBO J."},{"key":"10.1016\/j.abb.2018.10.011_bib239","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1744806916646110","article-title":"Inefficient constitutive inhibition of P2X3 receptors by brain natriuretic peptide system contributes to sensitization of trigeminal sensory neurons in a genetic mouse model of familial hemiplegic migraine","volume":"12","author":"Marchenkova","year":"2016","journal-title":"Mol. Pain"},{"key":"10.1016\/j.abb.2018.10.011_bib240","doi-asserted-by":"crossref","first-page":"11595","DOI":"10.1073\/pnas.1305461110","article-title":"Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception","volume":"110","author":"Akgun","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.abb.2018.10.011_bib241","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.bbamcr.2016.07.009","article-title":"Heterodimerization of the kappa opioid receptor and neurotensin receptor 1 contributes to a novel \u03b2-arrestin-2-biased pathway","volume":"1863","author":"Liu","year":"2016","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.abb.2018.10.011_bib242","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.2174\/0929867323666161024151734","article-title":"Multitarget opioid\/non-opioid ligands: a potential approach in pain management","volume":"23","author":"Turnaturi","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib243","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.4155\/fmc.15.156","article-title":"The design of multitarget ligands for chronic and neuropathic pain","volume":"7","author":"Dvoracsko","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.abb.2018.10.011_bib244","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.sbi.2017.02.005","article-title":"Network analysis and in silico prediction of protein-protein interactions with applications in drug discovery","volume":"44","author":"Murakami","year":"2017","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.abb.2018.10.011_bib245","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1517\/17425247.2012.717068","article-title":"Oral delivery of peptides and proteins using lipid-based drug delivery systems","volume":"9","author":"Li","year":"2012","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.abb.2018.10.011_bib246","doi-asserted-by":"crossref","first-page":"185\/1","DOI":"10.3390\/ijms17020185","article-title":"Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos","volume":"17","author":"Kristensen","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.abb.2018.10.011_bib247","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1039\/C5SC04392A","article-title":"Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides","volume":"7","author":"Moradi","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.abb.2018.10.011_bib248","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fphar.2013.00155","article-title":"Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain","volume":"4","author":"Varamini","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.abb.2018.10.011_bib249","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1021\/acsami.6b13176","article-title":"Sequence-controlled delivery of peptides from hierarchically structured nanomaterials","volume":"9","author":"He","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.abb.2018.10.011_bib250","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/1061186X.2017.1400552","article-title":"The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation","volume":"26","author":"Wong","year":"2018","journal-title":"J. Drug Target."},{"key":"10.1016\/j.abb.2018.10.011_bib251","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijpharm.2018.02.038","article-title":"Lipid-based nanosuspensions for oral delivery of peptides, a critical review","volume":"541","author":"Dumont","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.abb.2018.10.011_bib252","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00228-017-2301-8","article-title":"Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm","volume":"73","author":"Taneja1","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Archives of Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000398611830599X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000398611830599X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T06:08:10Z","timestamp":1757743690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000398611830599X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":251,"alternative-id":["S000398611830599X"],"URL":"https:\/\/doi.org\/10.1016\/j.abb.2018.10.011","relation":{},"ISSN":["0003-9861"],"issn-type":[{"value":"0003-9861","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent progress in non-opioid analgesic peptides","name":"articletitle","label":"Article Title"},{"value":"Archives of Biochemistry and Biophysics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abb.2018.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}